VR Adviser’s Enliven Therapeutics ELVN Stock Holding History

VR Adviser’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$67.7M	Sell	1,726,331 -1,500,000	-46%	-$41.6M	2.53%	12
2025 Q4	$49.7M	Hold	3,226,331	–	–	2.45%	13
2025 Q3	$66M	Sell	3,226,331 -800,000	-20%	-$16.1M	3.72%	9
2025 Q2	$80.8M	Hold	4,026,331	–	–	6.05%	4
2025 Q1	$79.2M	Hold	4,026,331	–	–	6.74%	4
2024 Q4	$90.6M	Hold	4,026,331	–	–	6.22%	3
2024 Q3	$103M	Hold	4,026,331	–	–	5.39%	3
2024 Q2	$94.1M	Hold	4,026,331	–	–	5.99%	2
2024 Q1	$70.8M	Buy	4,026,331 +1,071,429	+36%	+$16.4M	3.37%	8
2023 Q4	$40.9M	Hold	2,954,902	–	–	2.8%	10
2023 Q3	$40.4M	Buy	2,954,902 +724,775	+32%	+$12.2M	4.25%	7
2023 Q2	$45.5M	Buy	2,230,127 +15,985	+0.7%	+$323K	7.28%	4
2023 Q1	$48.5M	Buy	+2,214,142	New	+$45M	9.47%	3

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VR Adviser's ELVN Position: Q1 2026 in Review

VR Adviser reduced its Enliven Therapeutics (ELVN) stake by 46% in Q1 2026, selling an estimated $41.6M and leaving 1,726,331 shares worth $67.7M. The position accounts for 2.53% of the portfolio, ranked #12.

VR Adviser first reported a position in ELVN in Q1 2023 and has held it in 13 quarters since. The position peaked at $103M in Q3 2024. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

VR Adviser held 1,726,331 shares of Enliven Therapeutics worth $67.7M as of Q1 2026.
VR Adviser sold 1,500,000 Enliven Therapeutics shares in Q1 2026, an estimated $41.6M.
Enliven Therapeutics made up 2.53% of VR Adviser's portfolio in Q1 2026, its #12 holding.
VR Adviser first reported a position in Enliven Therapeutics in Q1 2023 and has held it in 13 quarters since.
VR Adviser's Enliven Therapeutics position peaked at $103M in Q3 2024.
170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.